Penthrox: Key Details on Mechanism and Safe Usage

Penthrox is a handheld, disposable inhaler that delivers low-dose methoxyflurane, a volatile fluorinated hydrocarbon, for short-term pain relief. It works by acting on two key targets in the central nervous system: boosting the activity of inhibitory GABA-A receptors while dampening excitatory NMDA receptor signaling, which together reduce the brain’s ability to process pain signals.¹ Though methoxyflurane was once used at high doses as a general anesthetic, that practice was abandoned decades ago over kidney safety concerns. In its current low-dose form, the drug has built a long track record in emergency and prehospital settings, particularly in Australia, and has gained broader regulatory approval in Europe and other regions.

How the Inhaler Works in Practice

The Penthrox device is about the size of a marker pen. A healthcare provider loads a small vial of liquid methoxyflurane (typically 3 mL) into the inhaler, and the patient breathes through it at their own pace. This self-administration is one of its defining practical advantages: the patient controls the dose breath by breath, which naturally limits intake because a person in pain tends to inhale more deeply, while someone whose pain is easing breathes more gently. An activated-carbon chamber on the device captures exhaled vapor, reducing the amount released into the surrounding air.

The device requires no intravenous access, no specialized monitoring equipment, and minimal training. That portability makes it particularly useful in ambulances, on sports fields, and in busy emergency departments where establishing an IV line takes time and staff attention.² In one prospective observational study, about 61% of patients achieved sufficient pain relief from methoxyflurane alone, without needing any additional analgesic. Technical issues with filling the inhaler were noted in roughly 15% of cases, though these were typically minor.

How Quickly It Relieves Pain

Speed of onset is where Penthrox stands out most clearly. In a double-blind, placebo-controlled trial (the STOP! study), patients who inhaled methoxyflurane experienced a median time to first pain relief of four minutes, compared with ten minutes for those given a placebo inhaler. The overall treatment effect was substantial, with methoxyflurane reducing pain scores by an estimated 15.1 mm more than placebo on a standard visual analog scale, and roughly 87% of patients in the methoxyflurane group reported experiencing pain relief.³

The Italian MEDITA trial, a large multicenter randomized study, confirmed these findings in a real-world emergency setting. Methoxyflurane produced significantly greater pain reduction within the first ten minutes compared with standard analgesic treatment, and this held for both moderate and severe pain.⁴ That rapid onset matters in acute trauma, where the first ten to fifteen minutes of pain are often the worst and the hardest to manage with conventional drugs that need time to be drawn up and injected.

How It Compares with Morphine, Fentanyl, and Nitrous Oxide

Several trials have now pitted methoxyflurane against the most commonly used emergency analgesics. A three-arm Norwegian trial (PreMeFen) randomized prehospital patients to inhaled methoxyflurane, intranasal fentanyl, or intravenous morphine. At ten minutes, methoxyflurane produced the largest drop in pain scores and was statistically non-inferior to both comparators. Intranasal fentanyl, interestingly, failed to meet the non-inferiority threshold against morphine at that time point, while methoxyflurane cleared it comfortably.⁵

A subgroup analysis of the MEDITA trial focusing on severe trauma pain found that methoxyflurane achieved a faster onset than intravenous morphine, with a median time to pain relief of nine minutes versus fifteen minutes for morphine.⁶ That gap reflects a real practical advantage: morphine requires placing an IV line first, which adds minutes to the process and demands more staff involvement.

In a controlled volunteer study using experimental pain (the cold pressor test), inhaled methoxyflurane provided pain relief equivalent to a low dose of intravenous fentanyl (25 micrograms), though it was less potent than a higher fentanyl dose (50 micrograms).⁷ Against nitrous oxide, a systematic review and indirect comparison found that both agents provided similarly rapid pain relief in trauma patients with no significant difference between them.⁸ In dental surgery, patients who tried both methods actually preferred methoxyflurane over nitrous oxide sedation, though sedation depth at fifteen minutes was lighter with methoxyflurane.⁹

So the picture is not that Penthrox is the strongest analgesic available. It is that for moderate to severe acute pain, it provides comparable relief to standard opioids and nitrous oxide, but gets there faster and with far less logistical overhead.

Dose Limits and Why They Exist

The kidney safety story of methoxyflurane is essentially a story about dose. When the drug was used at full anesthetic concentrations in the 1960s and 1970s, some patients developed a form of kidney damage linked to fluoride ions released during the body’s breakdown of the drug. The enzyme primarily responsible for this breakdown is cytochrome P450 2E1 in the liver, which strips fluoride atoms from the methoxyflurane molecule.¹⁰ At anesthetic doses, enough fluoride accumulated in the blood to damage kidney tubules. At the much lower analgesic doses used in Penthrox, fluoride levels stay well below the threshold associated with harm.

Current guidelines limit methoxyflurane to a maximum of 6 mL per day and 15 mL per week. At those doses, the drug produces roughly 0.59 MAC-hours of exposure, which gives it a safety margin of at least 2.7-fold to 8-fold below the level associated with kidney toxicity, depending on whether you measure by MAC-hours or serum fluoride concentration.¹¹ In practice, most patients use a single 3 mL inhaler per episode, which is half the daily maximum.

Reviews of clinical data at these analgesic doses have found no significant adverse effects on the kidneys, either in patients or in healthcare workers exposed occupationally.¹² That said, uncertainty remains about its safety in people with pre-existing kidney disease, and most guidelines treat known renal impairment as a contraindication or at least a strong caution.¹³ Repeated use over a short period should also be avoided, and clinicians are advised against combining it with other potentially nephrotoxic drugs or agents that induce CYP450 2E1 activity.

Side Effects and Adverse Events

At analgesic doses, the most frequently reported side effects are dizziness, lightheadedness, a feeling of relaxation or mild euphoria, and occasionally nausea. These are the expected effects of a very low-concentration inhaled anesthetic acting on the central nervous system, and they typically resolve within minutes of stopping inhalation.

In the PreMeFen trial comparing methoxyflurane against morphine and fentanyl, adverse event rates were virtually identical across all three arms: about 22% for methoxyflurane, 24% for morphine, and 24% for fentanyl. Two serious adverse events (respiratory depression and loss of consciousness) occurred in one patient in the methoxyflurane group.⁵ These events are rare and broadly in line with the risks seen with opioid analgesics used in the same setting.

Use in Children and Adolescents

One of the areas where Penthrox fills a genuine gap is pediatric pain. Getting an IV line into a distressed child with a broken arm is difficult, slow, and sometimes traumatic in its own right. An inhaler that a child can hold and breathe through on their own is a fundamentally different experience.

The MAGPIE trial, a randomized placebo-controlled study of children and adolescents aged 6 to 17, found that methoxyflurane reduced pain scores significantly more than placebo at fifteen minutes, with a mean difference of about 7 mm on the visual analog scale. Perhaps more telling, only about 10% of children in the methoxyflurane group required rescue medication, compared with 30% in the placebo group. Physicians gave methoxyflurane much higher performance ratings, with roughly five times greater odds of a positive assessment compared with placebo.¹⁴

Adverse events were somewhat more common in the methoxyflurane group (64% versus 55% for placebo), driven primarily by dizziness (about 41% versus 12%) and euphoric mood (12% versus 0%). None of the adverse events were classified as serious. A separate large retrospective cohort study of children and adolescents treated with methoxyflurane by ambulance services found no cases of liver or kidney toxicity and no increase in hospitalization or death associated with its use.¹⁵ The safety profile in children appears consistent with what is seen in adults.

Procedural Uses Beyond Trauma

While emergency trauma pain is the headline use, Penthrox has found a role in a range of painful medical procedures. During the COVID-19 pandemic, one UK hospital used it extensively for fracture manipulations and joint reductions that would normally require full procedural sedation, which demands more staff, monitoring, and time. Over a two-month period, fracture manipulations performed with Penthrox analgesia achieved a 100% success rate for adequate reduction, and elbow dislocations were reduced successfully in all cases. Shoulder dislocations had a lower success rate of about 65%, reflecting the anatomy of that joint rather than a failure of analgesia.¹⁶ No complications were recorded.

It has also been studied for use during bone marrow biopsies, wound care, dental procedures, lumbar epidural injections, and abscess drainage. The common thread across these applications is the same: Penthrox is useful whenever a procedure causes short-lived moderate-to-severe pain and the logistical burden of IV sedation is disproportionate to the duration of the painful stimulus.

Occupational Exposure for Healthcare Workers

When a patient breathes out through the Penthrox inhaler, the activated-carbon chamber captures most of the exhaled methoxyflurane vapor. But some vapor inevitably escapes into the room, raising a reasonable question about the safety of the healthcare workers standing nearby, especially nurses who may supervise multiple administrations per shift.

The derived maximum occupational exposure limit for methoxyflurane is 15 parts per million over an eight-hour time-weighted average. Multiple workplace monitoring studies have found actual exposure levels far below that threshold. In French hospital emergency rooms, the median exposure measured on personal badge samplers during eight-hour nursing shifts was 0.017 ppm, roughly 900 times below the limit. Even on shifts where up to five Penthrox inhalers were used, there was no correlation between the number of administrations and the vapor concentration measured on the badges.¹⁷

A UK study during bone marrow biopsy sessions found slightly higher exposures, with a median of 0.38 ppm across all staff, and a maximum of 2.88 ppm for one nurse on a particularly busy session. Even that peak was well below the 15 ppm ceiling.¹⁸ A broader analysis covering ambulance workers and hospital staff found that in typically ventilated treatment environments, the derived exposure limit was at least 50 times higher than the mean observed concentrations.¹⁹ Standard room ventilation appears sufficient; dedicated scavenging systems, while sometimes used, are not strictly necessary in most clinical spaces.

Cost and Operational Efficiency

Penthrox has an appealing economic profile, largely because it simplifies the workflow around pain management. When a patient can inhale their own analgesic instead of needing IV cannulation, procedural sedation, and the associated monitoring, you save staff time, free up clinical space, and reduce the overall time a patient spends in the emergency department.

An Australian cost-minimization analysis estimated that methoxyflurane use was associated with lower per-patient costs than standard care, with estimated savings ranging from 62 to 283 Australian dollars per patient compared with intranasal fentanyl, and 339 to 560 dollars compared with intravenous ketamine. Extrapolated nationally, that represented potential annual efficiency gains of 9.5 to 85 million dollars across Australian emergency departments.²⁰ In the UK, a service evaluation calculated that using methoxyflurane instead of procedural sedation for upper limb injuries could save roughly £82 per patient, driven by reduced staff time and shorter emergency department stays.²¹

A systematic review and meta-analysis confirmed the pattern: patients receiving inhaled methoxyflurane for limb injury reduction had shorter emergency department stays, fewer adverse events, and higher satisfaction scores compared with those undergoing standard procedural sedation.²²

Environmental Footprint

Methoxyflurane is a fluorinated compound, which invites the question of whether it contributes meaningfully to climate change or ozone depletion. Atmospheric chemistry research shows that methoxyflurane is a short-lived compound with an estimated atmospheric lifetime of about 54 days. Its ozone depletion potential is on the order of 0.001 (essentially negligible), and its 100-year global warming potential is just 4, meaning each kilogram traps about four times as much heat as a kilogram of carbon dioxide over a century.²³ For comparison, nitrous oxide (the other common inhaled analgesic) has a global warming potential around 265 and persists in the atmosphere for over a century.

A full life-cycle assessment found that a single Penthrox inhaler produces about 0.84 kg of carbon dioxide equivalent, with the raw materials and manufacturing process accounting for most of the impact. When compared directly against a standard administration of Entonox (the 50/50 nitrous oxide-oxygen mixture widely used in ambulances and emergency departments), Penthrox had roughly 118 times less climate change impact.²⁴ The device itself is disposable, which creates some plastic waste, but from a greenhouse gas perspective, the comparison heavily favors methoxyflurane over nitrous oxide.

Global Availability and Regulatory History

Methoxyflurane has been used as a low-dose analgesic in Australia for over four decades, where it is commonly known as the “green whistle” for the color of the inhaler device.² It was approved in Europe in 2015 for moderate-to-severe trauma-related pain in adults, and has since been authorized in a number of additional countries.²⁵ Uptake has varied considerably: it is well established in emergency departments and ambulance services across Australia, New Zealand, and parts of Europe, but remains less commonly used in the United Kingdom and is not approved in the United States, where the legacy association with nephrotoxicity from the anesthetic era still lingers in regulatory memory.

That regulatory caution is understandable given the history, but the evidence base for the low-dose analgesic formulation is now extensive. The gap between the anesthetic doses that caused kidney damage and the analgesic doses delivered by Penthrox is wide, well-characterized, and supported by decades of real-world use. For clinicians and patients in settings where it is available, Penthrox represents a genuinely different option in the acute pain toolkit: fast-acting, self-administered, non-opioid, portable, and supported by a growing body of randomized evidence across both adult and pediatric populations.